219 related articles for article (PubMed ID: 16648986)
1. [Innovation or pseudo-innovation: that is the question].
Unger T
Med Klin (Munich); 2006 Mar; 101(3):257-62. PubMed ID: 16648986
[No Abstract] [Full Text] [Related]
2. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
Anlauf M; Hense HW
Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
[No Abstract] [Full Text] [Related]
3. [Hypertension therapy--never without diuretics?].
Anlauf M
MMW Fortschr Med; 2007 Nov; 149(46):31-3. PubMed ID: 18069189
[TBL] [Abstract][Full Text] [Related]
4. [Economic or medical innovations: that is the question!].
Freitag MH; Wohlgemuth WA
Med Klin (Munich); 2006 Jul; 101(7):590-1; author reply 591-3. PubMed ID: 16897896
[No Abstract] [Full Text] [Related]
5. [Comment on IOWiG report plan. A medical decision may not be replaced].
Vorstand der Deutschen Hochdruckliga E.V
MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
[No Abstract] [Full Text] [Related]
6. [Therapy of hypertension. Cost conscious prevention of complications].
Kolloch RE
MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042
[No Abstract] [Full Text] [Related]
7. Hypertension control: improved, but not enough!
Alderman MH
Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
[No Abstract] [Full Text] [Related]
8. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
Amira CO; Okubadejo NU
J Hum Hypertens; 2006 Nov; 20(11):894-7. PubMed ID: 16915299
[No Abstract] [Full Text] [Related]
9. [Fully possible to reduce the costs of hypertension treatment].
Wettermark B; Angman A; Hjemdahl P
Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
[No Abstract] [Full Text] [Related]
10. [Treating hypertension only in case of high risk? Evidence-based therapy with cost control].
Trenkwalder P
MMW Fortschr Med; 2001 Feb; 143(7):45-6. PubMed ID: 11268751
[No Abstract] [Full Text] [Related]
11. From clinical trials to clinical practice: why the gap?
Kotchen TA
Hypertension; 2006 Aug; 48(2):196-7. PubMed ID: 16785333
[No Abstract] [Full Text] [Related]
12. Thiazides first-line treatment for hypertension.
McCormack J; Rangno R; Wright JM
Can Fam Physician; 2003 Jul; 49():879. PubMed ID: 12901483
[No Abstract] [Full Text] [Related]
13. [Unfairly implicated as cost drivers. New drugs without a chance?].
MMW Fortschr Med; 2004 Mar; 146(10):45. PubMed ID: 15347085
[No Abstract] [Full Text] [Related]
14. Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.
Robbiano L; Martelli A; Brambilla G
J Hum Hypertens; 2005 Oct; 19(10):819-22. PubMed ID: 15951739
[No Abstract] [Full Text] [Related]
15. [Rational introduction to new drugs requires both a health care and a community perspective].
Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergendahl GT; Wiking N
Lakartidningen; 2009 Jan 7-13; 106(1-2):52. PubMed ID: 19235325
[No Abstract] [Full Text] [Related]
16. [Health care too costly? Saving more than 10 million euros in 2 months!].
Rappert B
MMW Fortschr Med; 2003 Nov; 145(47):65. PubMed ID: 14725043
[No Abstract] [Full Text] [Related]
17. [Pharmacoeconomic issues in antihypertensive treatment].
Saito I
Nihon Rinsho; 2006 Aug; 64 Suppl 6():271-5. PubMed ID: 16981554
[No Abstract] [Full Text] [Related]
18. [Development of new drugs is too expensive].
Andreasen J
Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
[No Abstract] [Full Text] [Related]
19. [Structured introduction of new drug therapies: valuable initiative--transparency required].
Lundkvist J; Henriksson F
Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324
[No Abstract] [Full Text] [Related]
20. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-MartÃnez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]